Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients
Status:
Completed
Trial end date:
2018-11-14
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to investigate the safety and efficacy of BI 655130 in
patients with PPP following multiple intravenous administrations compared to placebo.